# Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

> **NCT01254526** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** GDC-0980
- **DRUG:** bevacizumab
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT01254526
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-07
- **Final completion:** 2013-04
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254526, "Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01254526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*